Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drugs has demonstrated a statistically significant and clinically meaningful improvement in overall survival when administered as adjuvant therapy to appropriately selected patients with Stage IB to IIIA non-small cell lung cancer (NSCLC)?
   a. Pembrolizumab
   b. Atezolizumab
   c. Durvalumab
   d. Osimertinib
   e. None of the above

2. Which of the following approaches is being compared to platinum-based chemotherapy in the Phase III NeoADAURA study for patients with resectable Stage II to IIIB NSCLC?
   a. Osimertinib in combination with platinum-based chemotherapy
   b. Osimertinib monotherapy
   c. Osimertinib as monotherapy and in combination with platinum-based chemotherapy

3. The Phase III AEGEAN study demonstrated a statistically significant improvement in EFS with which of the following drugs compared to placebo, each in combination with platinum-based chemotherapy, for patients with treatment-naïve, resectable NSCLC?
   a. Atezolizumab
   b. Durvalumab
   c. Nivolumab
   d. Pembrolizumab

4. A statistically significant improvement in disease-free survival with adjuvant pembrolizumab was reported in which of the following patient populations on the Phase III KEYNOTE-091/PEARLS study?
   a. Patients with PD-L1 >50%
   b. Patients with Stage IB to IIIA disease
   c. Both a and b
   d. Neither a nor b

5. A prespecified interim analysis of the Phase III ALINA study reported a statistically significant and clinically meaningful improvement in disease-free survival with which therapy compared to platinum-based chemotherapy for patients with resectable NSCLC and ALK rearrangements?
   a. Adjuvant lorlatinib
   b. Neoadjuvant lorlatinib
   c. Adjuvant ceritinib
   d. Neoadjuvant ceritinib
   e. Adjuvant brigatinib
   f. Neoadjuvant brigatinib
   g. Adjuvant alectinib
   h. Neoadjuvant alectinib

QID 4849